1. Bone Pain and Muscle Weakness in Cancer Patients
- Author
-
Teresa A. Zimmers, Daniel P. Milgrom, Neha Lad, and Leonidas G. Koniaris
- Subjects
0301 basic medicine ,Sarcopenia ,medicine.medical_specialty ,Cachexia ,Endocrinology, Diabetes and Metabolism ,Bone Neoplasms ,Bioinformatics ,Article ,Bone and Bones ,03 medical and health sciences ,Physical medicine and rehabilitation ,Neoplasms ,medicine ,Humans ,Bone pain ,Wasting ,Muscle Weakness ,business.industry ,Bone metastasis ,Cancer ,Muscle weakness ,Cancer Pain ,medicine.disease ,030104 developmental biology ,Current management ,Hypercalcemia ,Bone Diseases ,medicine.symptom ,business - Abstract
In this article, we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancer-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. There are several pharmacologic therapies that are currently in preclinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of noceciptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. CIBP and CIMW are significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.
- Published
- 2017
- Full Text
- View/download PDF